Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    10363983 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Velcade/Dexamethasone
2 Completed A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Condition: Follicular Lymphoma
Intervention: Drug: Bortezomib and Tositumomab I-131
3 Completed Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.
Condition: Multiple Myeloma
Interventions: Drug: Velcade;   Drug: Melphalan;   Drug: Prednisone

Indicates status has not been verified in more than two years